Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for four months after treatment
Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatment
Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatment
Willing to practice birth control during treatment and for four months after receiving the treatment
Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatment.
Willing to practice birth control during treatment and for four months after receiving the treatment
Subjects of both genders of child-bearing potential who are not willing to practice birth control from the time of consent through 6 months after the completion of KTE-C19
Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for four months after treatment
Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatment
Patients of both genders must be willing to practice birth control during and for four months after receiving chemotherapy
Male patients and must be willing to practice birth control from the time of enrollment on this study and for four months following the final CAR T cell infusion; pre-menopausal patients (female patients who have had a menstrual period within the last year) must be willing to practice birth control from the time of enrollment and for one year following the final CAR T cell infusion
Patients of both genders must be willing to practice birth control from the time of enrollment on this study up to four months after treatment; patients must be willing to undergo testing for HPV-16 prior to becoming pregnant after this period
Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatment
Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after cells are no longer detected in the blood
Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for four months after receiving the preparative regimen
Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatment
Patients of both genders must practice birth control for four months after receiving the preparative regimen (lymphodepletion) and continue to practice birth control throughout the study; patients must have a documented negative pregnancy test (urine or serum) for women who have menstruated in the past 12 months and without sterilization surgery
Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatment
Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatment
Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatment
Patients of both genders must practice birth control for four months after receiving the preparative regimen (lymphodepletion) and continue to practice birth control throughout the study; patients must have a documented negative pregnancy test (urine or serum) for women who have menstruation in the past 12 months and without sterilization surgery (Turnstile II)
Patients of both genders must practice birth control for four months after receiving the preparative regimen (lymphodepletion) and continue to practice birth control throughout the study; patients must have a documented negative pregnancy test (urine or serum) for women who have menstruation in the past 12 months and without sterilization surgery (Turnstile II)
Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for four months after treatment
Patients of both genders must practice birth control for four months after receiving the preparative regimen (Turnstile II - Chemotherapy/Cell Infusion - Inclusion Criteria)
Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after receiving the treatment
Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for four months after receiving the preparative regimen
Patients of both genders must be willing to practice birth control during and for four months after receiving chemotherapy
Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after receiving the treatment
Subjects of both genders of child-bearing potential who are not willing to practice birth control from the time of consent through 6 months after the completion of KTE-C19
Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after receiving the treatment
Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for four months after treatment
Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatment
Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatment
TREATMENT: Patients must be willing to practice birth control during and for four months following treatment
Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatment
Patients of both genders must be willing to practice birth control from the time of enrollment on this study up to 4 months after treatment; patients must be willing to undergo testing for HPV-16 prior to becoming pregnant
Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after receiving treatment
Patients of both genders must be willing to practice birth control from the time of enrollment on the study and for four months after treatment
Patients must be willing to practice birth control during and for four months following treatment
Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatment
Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatment
Male patients must be willing to practice birth control (including abstinence) during and for 4 months after treatment. Female patients must be willing to practice birth control (including abstinence) during treatment and for 4 months after gene modified cells are no longer detected in body.
Subjects of both genders of child-bearing potential who are not willing to practice birth control from the time of consent through 6 months after the completion of KITE-718
